NURS617 EXAM 1 Actual Exam 2026/2027 Complete
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
• A. aPTT; 1.5-2.5 times control
• B. INR; 2.0-3.0 [CORRECT]
• C. Anti-Xa; 0.5-1.0 IU/mL
• D. Bleeding time; 3-9 minutes
Correct Answer: B Rationale: Warfarin's anticoagulant effect is monitored using the
International Normalized Ratio (INR). For most indications, including atrial fibrillation and
venous thromboembolism, the therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor
unfractionated heparin. Anti-Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to
monitor warfarin.
Q2: A patient taking carbamazepine for seizures is prescribed simvastatin for hyperlipidemia.
The NP recognizes that carbamazepine may reduce simvastatin efficacy because carbamazepine
is a:
• A. CYP3A4 inhibitor
• B. CYP3A4 inducer [CORRECT]
• C. CYP2D6 inhibitor
• D. CYP2C9 substrate
Correct Answer: B Rationale: Carbamazepine is a potent CYP3A4 enzyme inducer (B), which
increases the metabolism of simvastatin (a CYP3A4 substrate), thereby reducing its efficacy.
CYP3A4 inhibitors (A) would increase simvastatin levels and toxicity risk. CYP2D6 (C) and
CYP2C9 (D) are not primarily involved in simvastatin metabolism.
,Q3: A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The NP anticipates that the drug's bioavailability will:
• A. Decrease significantly
• B. Increase significantly [CORRECT]
• C. Remain unchanged
• D. Become unpredictable
Correct Answer: B Rationale: In liver cirrhosis, impaired hepatic function reduces first-pass
metabolism, allowing more drug to enter systemic circulation unchanged, thereby significantly
increasing bioavailability (B). This necessitates dose reduction to prevent toxicity. First-pass
metabolism would not decrease (A), remain unchanged (C), or become merely unpredictable
(D)—it predictably decreases.
Q4: A 45-year-old patient with anxiety is prescribed propranolol. The NP understands this beta-
blocker is non-selective and will block which receptors?
• A. Beta-1 receptors only
• B. Beta-2 receptors only
• C. Both beta-1 and beta-2 receptors [CORRECT]
• D. Alpha-1 and beta-1 receptors
Correct Answer: C Rationale: Propranolol is a non-selective beta-blocker that antagonizes both
beta-1 (cardiac) and beta-2 (pulmonary/vascular) receptors (C). Beta-1 selective blockers (A)
include metoprolol and atenolol. Beta-2 only blockers (B) do not exist clinically. Alpha and beta
blockers (D) describe agents like labetalol or carvedilol.
Q5: A patient with chronic kidney disease is prescribed a drug with a narrow therapeutic index
that is 90% renally excreted unchanged. The NP should prioritize monitoring:
• A. Liver function tests
• B. Drug levels and renal function [CORRECT]
• C. Pulmonary function tests
• D. Thyroid function tests
, Correct Answer: B Rationale: For drugs with narrow therapeutic indices that are primarily
renally excreted, dose adjustment based on renal function and therapeutic drug monitoring are
essential to prevent toxicity (B). Liver function (A) is less relevant for renally cleared drugs.
Pulmonary (C) and thyroid (D) functions are not directly relevant to this pharmacokinetic
scenario.
Q6: A patient is prescribed codeine for postoperative pain. The NP recognizes that codeine is a
prodrug that requires conversion to morphine by which enzyme to provide analgesia?
• A. CYP2C19
• B. CYP2D6 [CORRECT]
• C. CYP3A4
• D. CYP1A2
Correct Answer: B Rationale: Codeine is a prodrug that requires O-demethylation by CYP2D6
to convert to morphine, its active metabolite responsible for analgesia (B). Poor metabolizers
(CYP2D6) experience inadequate pain relief, while ultrarapid metabolizers are at risk for
toxicity. CYP2C19 (A), CYP3A4 (C), and CYP1A2 (D) are not primarily responsible for this
conversion.
Q7: A patient on multiple medications develops sudden muscle pain and weakness. The NP
suspects rhabdomyolysis and reviews the medication list. Which combination most likely caused
this adverse effect?
• A. Amlodipine and lisinopril
• B. Atorvastatin and clarithromycin [CORRECT]
• C. Metformin and glipizide
• D. Levothyroxine and omeprazole
Correct Answer: B Rationale: Clarithromycin is a potent CYP3A4 inhibitor that significantly
increases atorvastatin levels, markedly increasing the risk of myopathy and rhabdomyolysis (B).
Amlodipine/lisinopril (A), metformin/glipizide (C), and levothyroxine/omeprazole (D)
combinations do not carry this specific interaction risk.
Q8: A patient with G6PD deficiency develops hemolytic anemia after taking a sulfonamide
antibiotic. This reaction exemplifies which type of pharmacogenomic consideration?
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin. The NP understands that
warfarin's anticoagulant effect is monitored using which laboratory value, and what is the
therapeutic range for most indications?
• A. aPTT; 1.5-2.5 times control
• B. INR; 2.0-3.0 [CORRECT]
• C. Anti-Xa; 0.5-1.0 IU/mL
• D. Bleeding time; 3-9 minutes
Correct Answer: B Rationale: Warfarin's anticoagulant effect is monitored using the
International Normalized Ratio (INR). For most indications, including atrial fibrillation and
venous thromboembolism, the therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor
unfractionated heparin. Anti-Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to
monitor warfarin.
Q2: A patient taking carbamazepine for seizures is prescribed simvastatin for hyperlipidemia.
The NP recognizes that carbamazepine may reduce simvastatin efficacy because carbamazepine
is a:
• A. CYP3A4 inhibitor
• B. CYP3A4 inducer [CORRECT]
• C. CYP2D6 inhibitor
• D. CYP2C9 substrate
Correct Answer: B Rationale: Carbamazepine is a potent CYP3A4 enzyme inducer (B), which
increases the metabolism of simvastatin (a CYP3A4 substrate), thereby reducing its efficacy.
CYP3A4 inhibitors (A) would increase simvastatin levels and toxicity risk. CYP2D6 (C) and
CYP2C9 (D) are not primarily involved in simvastatin metabolism.
,Q3: A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. The NP anticipates that the drug's bioavailability will:
• A. Decrease significantly
• B. Increase significantly [CORRECT]
• C. Remain unchanged
• D. Become unpredictable
Correct Answer: B Rationale: In liver cirrhosis, impaired hepatic function reduces first-pass
metabolism, allowing more drug to enter systemic circulation unchanged, thereby significantly
increasing bioavailability (B). This necessitates dose reduction to prevent toxicity. First-pass
metabolism would not decrease (A), remain unchanged (C), or become merely unpredictable
(D)—it predictably decreases.
Q4: A 45-year-old patient with anxiety is prescribed propranolol. The NP understands this beta-
blocker is non-selective and will block which receptors?
• A. Beta-1 receptors only
• B. Beta-2 receptors only
• C. Both beta-1 and beta-2 receptors [CORRECT]
• D. Alpha-1 and beta-1 receptors
Correct Answer: C Rationale: Propranolol is a non-selective beta-blocker that antagonizes both
beta-1 (cardiac) and beta-2 (pulmonary/vascular) receptors (C). Beta-1 selective blockers (A)
include metoprolol and atenolol. Beta-2 only blockers (B) do not exist clinically. Alpha and beta
blockers (D) describe agents like labetalol or carvedilol.
Q5: A patient with chronic kidney disease is prescribed a drug with a narrow therapeutic index
that is 90% renally excreted unchanged. The NP should prioritize monitoring:
• A. Liver function tests
• B. Drug levels and renal function [CORRECT]
• C. Pulmonary function tests
• D. Thyroid function tests
, Correct Answer: B Rationale: For drugs with narrow therapeutic indices that are primarily
renally excreted, dose adjustment based on renal function and therapeutic drug monitoring are
essential to prevent toxicity (B). Liver function (A) is less relevant for renally cleared drugs.
Pulmonary (C) and thyroid (D) functions are not directly relevant to this pharmacokinetic
scenario.
Q6: A patient is prescribed codeine for postoperative pain. The NP recognizes that codeine is a
prodrug that requires conversion to morphine by which enzyme to provide analgesia?
• A. CYP2C19
• B. CYP2D6 [CORRECT]
• C. CYP3A4
• D. CYP1A2
Correct Answer: B Rationale: Codeine is a prodrug that requires O-demethylation by CYP2D6
to convert to morphine, its active metabolite responsible for analgesia (B). Poor metabolizers
(CYP2D6) experience inadequate pain relief, while ultrarapid metabolizers are at risk for
toxicity. CYP2C19 (A), CYP3A4 (C), and CYP1A2 (D) are not primarily responsible for this
conversion.
Q7: A patient on multiple medications develops sudden muscle pain and weakness. The NP
suspects rhabdomyolysis and reviews the medication list. Which combination most likely caused
this adverse effect?
• A. Amlodipine and lisinopril
• B. Atorvastatin and clarithromycin [CORRECT]
• C. Metformin and glipizide
• D. Levothyroxine and omeprazole
Correct Answer: B Rationale: Clarithromycin is a potent CYP3A4 inhibitor that significantly
increases atorvastatin levels, markedly increasing the risk of myopathy and rhabdomyolysis (B).
Amlodipine/lisinopril (A), metformin/glipizide (C), and levothyroxine/omeprazole (D)
combinations do not carry this specific interaction risk.
Q8: A patient with G6PD deficiency develops hemolytic anemia after taking a sulfonamide
antibiotic. This reaction exemplifies which type of pharmacogenomic consideration?
